|
|
|
| Webinar: Understanding the Impact of IVT mRNA Impurities on Cellular Responses | Not all mRNA is created equal. But how much do impurities really impact therapeutic performance? Join Roche experts to explore how IVT mRNA impurities influence translation efficiency, reactogenicity, and cellular responses. Discover advanced analytical techniques for identifying critical impurities and learn how connecting purity profiles with biological functionality can strengthen quality control strategies for RNA-based therapeutics. Click here to learn more. |
|
|
|
|
By Robert Frederickson and Josh Eibelman, Goodwin | As RNA therapeutics grow more complex and collaborative, trade secrets are becoming an increasingly important part of protecting valuable platform innovation. | |
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | Outsourcing the components for RNA-based therapy programs is challenging. The partners you select depend on the area of RNA development you pursue. The task for all RNA sponsors is to think deeply about assembling development and manufacturing ecosystems, starting at the earliest stages of research and company formation. | |
|
|
|
By Advancing RNA Live | Though this Advancing RNA Live panel believes we’re still at too early a stage to begin reducing the number of methods we need for release, Sanofi’s Philippe Talaga, AbbVie’s Elaine Peters, and Tessera’s Ilya Shestopalov had a few ideas on what we can and should be doing today to set us up for more streamlined release panels in the future. | |
|
|
|
|
|
|
|
| Developing Robust mRNA Processes In A cGMP Environment | Poster | By Clemens Jakobi, Michal Domański, and Telmo Graça, Lonza | Evaluate current and emerging technologies to optimize mRNA manufacturing, especially when considering commercial production and the validation of processes in a cGMP environment. |
|
|
| Levers To Optimize The IVT Reaction For Increased mRNA Yield | Application Note | By Alexander Latta, Neera Sammeta, Stefan Kutter, Monika Seller, Bhawana Poudel-Bochmann, Peter Rasor, and Birgit Rogell, Roche CustomBiotech | Mastering IVT yield requires balancing magnesium and nucleotide ratios. Learn how specific buffers and pyrophosphatase optimize mRNA synthesis for scalable, high-quality therapeutic production. |
|
|
|
|
|
|
|
.png){kind=logo}
